IL1A and respiratory failure: An example of such a marker might be the soluble urokinase plasminogen activator receptor (suPAR) that predicts the progression to respiratory failure in COVID-19 patients and, targeting this pathway, the IL-1α/β inhibitor anakinra is now undergoing clinical trials (41, 54).